NCT00335179

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

Double-Blind, Vehicle-Controlled Study to Evaluate Cellular and Molecular Events During Four Weeks of Treatment for Actinic Keratosis With Aldara (Imiquimod) Cream, 5%

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Graceway Pharmaceuticals, LLC · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Treatment of actinic keratosis with imiquimod cream is expected to cause changes in the genes that are turned on, and turned off, by skin cells. Some of the drug induced changes in skin cells should also be visible using a special microscope. This study examines both types of changes.

Detailed description

The primary objective of this study was to assess apoptosis by examining the gene expression profiles of actinic keratosis (AK) lesions that were treated with imiquimod 5% cream or vehicle cream once daily 3 times per week for 4 weeks. Secondary objectives were to assess the utility of confocal microscopy (CM) to visually track cellular response to treatment with study cream compared with clinical and histological evaluations, and to evaluate the safety of treatment with imiquimod in subjects with AK on the balding scalp.

Conditions

• Actinic Keratosis

Interventions

Type	Name	Description
DRUG	Aldara (imiquimod 5% cream)	Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
DRUG	Vehicle cream	Vehicle cream in 250 mg

Timeline

• Start date: 2003-01-01
• Primary completion: 2003-07-01
• Completion: 2003-07-01
• First posted: 2006-06-09
• Last updated: 2010-07-23

Locations

1 site across 1 country: United States